Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 06, 2008. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, rather than a comprehensive financial results report.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity award transaction.
Material Changes
No material changes to financial performance or operational status are reported in this filing. The only disclosed event is a deferred investment award granted to a Person Discharging Managerial Responsibility.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It strictly details a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: June 02, 2008 (Notification received June 05, 2008).
- Recipient: Mr. S A Hussain, a Person Discharging Managerial Responsibility.
- Award Details: 35,778.18 Ordinary shares at a price of £11.18 per share.
- Vesting Schedule: 50% vests on June 02, 2012; 25% on June 02, 2013; and the remaining 25% on June 02, 2014.
- Financial Impact: This filing does not disclose the company's overall financial position or performance metrics.